ClinicalThought
View More
MACE and VTE data were presented for all approved and phase III JAK inhibitors.
Here’s how new strategies like ultralow-dose rituximab, a novel small molecule IRAK-4 inhibitor, and vagus nerve stimulation may or may not change clinical practice.
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270
Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.